Trials / Completed
CompletedNCT00921063
A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, 5-Week Trial To Assess The Efficacy And Safety Of PD 0332334 Compared To Placebo And Alprazolam Extended-Release In Patients With Generalized Anxiety Disorder
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 222 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of PD 0332334 compared to placebo in the treatment of Generalized Anxiety Disorder in an adult population
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PD 0332334 | 250 mg capsule, BID for 4 weeks |
| DRUG | PD 0332334 | 100 mg capsule, BID for 4 weeks |
| DRUG | placebo | 0 mg capsule, BID for 4 weeks |
| DRUG | Alprazolam extended release | 1 mg capsule, BID for 4 weeks |
Timeline
- Start date
- 2005-11-01
- Primary completion
- 2006-07-01
- Completion
- 2006-07-01
- First posted
- 2009-06-16
- Last updated
- 2010-02-19
Source: ClinicalTrials.gov record NCT00921063. Inclusion in this directory is not an endorsement.